Overview

A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine

Status:
Completed

Trial end date:
2005-12-01

Target enrollment:

Participant gender:

Summary

A 3 month, randomized, open label, multi-center study of Technosphere/Insulin compared to insulin aspart in subjects with type 1 diabetes mellitus receiving insulin glargine

Phase:

Phase 2

Details

Lead Sponsor:

Mannkind Corporation

Treatments:

Insulin
Insulin, Globin Zinc